Bevacizab 100mg

Bevacizab 100MG Inj is a brand name for Bevacizumab 100mg Injection, which is a medication used to treat various types of cancer. Here are some key points about the product:

Composition:

Each 100mg injection of Bevacizab contains 100mg of Bevacizumab, a monoclonal antibody that inhibits the activity of vascular endothelial growth factor (VEGF) and other VEGF receptors.

Indications:

Bevacizumab is indicated for the treatment of:

1. Metastatic colorectal cancer (mCRC)
2. Non-small cell lung cancer (NSCLC)
3. Renal cell carcinoma (RCC)
4. Ovarian cancer
5. Breast cancer

Mechanism of Action:

Bevacizumab works by:

1. Binding to VEGF and inhibiting its binding to VEGF receptors
2. Inhibiting the growth of new blood vessels and reducing tumor blood flow
3. Inhibiting the growth and spread of cancer cells

Dosage and Administration:

The recommended dosage of Bevacizab is:

• 100mg administered as an intravenous infusion every 2 weeks
• The dosage may be adjusted depending on the patient’s response to treatment

Side Effects:

Common side effects of Bevacizab include:

1. Hypertension
2. Proteinuria
3. Fatigue
4. Headache
5. Nausea and vomiting
6. Diarrhea
7. Abdominal pain
8. Bleeding or bruising
9. Skin changes

Serious side effects can include:

1. Gastrointestinal perforation
2. Hemorrhagic events (e.g., bleeding, hemolysis)
3. Reversible posterior leukoencephalopathy syndrome (RPLS)
4. Thrombosis or embolism
5. Cardiovascular events (e.g., heart failure, cardiac arrhythmias)

Contraindications:

Bevacizumab is contraindicated in patients with:

1. Known hypersensitivity to bevacizumab
2. Active bleeding or bleeding disorders
3. History of arterial thromboembolic events (e.g., stroke, myocardial infarction)
4. Pregnancy or breastfeeding (unless absolutely necessary)

Precautions:

1. Patients with a history of hypertension or cardiovascular disease should be closely monitored while receiving Bevacizumab.
2. Patients with a history of kidney disease or kidney dysfunction should receive dose reduction or close monitoring while receiving Bevacizumab.
3. Patients with a history of blood disorders should be closely monitored for signs of blood dyscrasias.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of infection, such as fever, chills, or sore throat.
• Patients should be advised to report any changes in their appetite, nausea, or vomiting.
• Patients should be informed that they may experience bleeding or bruising during treatment.

Storage and Handling:

• Store injections at room temperature between 15°C and 30°C (59°F and 86°F).
• Do not expose to direct sunlight or moisture.
• Use within 28 days of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.